retatrutide studie Research: Triple Agonist Mechanism and Clinical Studies Retatrutide Peptide: Triple Agonist Mechanism,

Weight loss injections like Wegovy (semaglutide), Zepbound (tirzepatide), and Mounjaro are clinically proven and effective medications

doi:10.1016/j.jdiacomp.2022.108255 21

Semaglutide (Wegovy) typically follows this schedule: Weeks 1-4: 0.25 mg Weeks 5-8: 0.5 mg Weeks 9-12: 1.0 mg Weeks 13-16: 1.7 mg Week 17+: 2.4 mg (maintenance) Tirzepatide (Zepbound) uses a similar approach: Weeks 1-4: 2.5 mg Weeks 5-8: 5 mg Weeks 9-12: 7.5 mg Weeks 13-16: 10 mg Week 17+: 12.5 mg or 15 mg (if tolerated) Do not self-adjust doses

Results Biodistribution study of [ 18 F]FB(ePEG12)12-exendin-4 In ex-vivo analyses using resected organs (n = 4 for each time point), the pancreatic uptake value of [ 18 F]FB(ePEG12)12-exendin-4 was high at 30-min post-injection (11.3 2.8%ID/g), remained high (12.7 2.9%ID/g) at 60-min time point and was modest (7.9 2.7%ID/g) at 150-min time point (Table 1)

Additionally, the lower concentration of benzyl alcohol found in bacteriostatic water for peptide reconstitution prevents it from affecting the stability or integrity of the peptide being dissolved in it